Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. CEO Ian Mortimer will present a fireside chat on Tuesday, June 10, 2025, from 3:20-3:55 PM ET. The presentation will be available via webcast on Xenon's website. The company focuses on developing ion channel products for epilepsy and depression, with their lead candidate azetukalner, a Kv7 potassium channel opener, in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (NASDAQ: XENE), un'azienda biofarmaceutica specializzata in neuroscienze, ha annunciato la sua partecipazione alla 46陋 Conferenza Globale Annuale sulla Salute di Goldman Sachs a Miami, FL. Il CEO Ian Mortimer terr脿 una conversazione informale marted矛 10 giugno 2025, dalle 15:20 alle 15:55 ET. La presentazione sar脿 disponibile in webcast sul sito web di Xenon. L'azienda si concentra sullo sviluppo di prodotti per i canali ionici per epilessia e depressione, con il loro candidato principale azetukalner, un apritore del canale potassio Kv7, in fase clinica avanzata per pi霉 indicazioni.
Xenon Pharmaceuticals (NASDAQ: XENE), una compa帽铆a biofarmac茅utica centrada en neurociencia, anunci贸 su participaci贸n en la 46陋 Conferencia Anual Global de Salud de Goldman Sachs en Miami, FL. El CEO Ian Mortimer presentar谩 una charla informal el martes 10 de junio de 2025, de 3:20 a 3:55 PM ET. La presentaci贸n estar谩 disponible v铆a webcast en el sitio web de Xenon. La empresa se enfoca en desarrollar productos para canales i贸nicos para epilepsia y depresi贸n, con su candidato principal azetukalner, un activador del canal de potasio Kv7, en desarrollo cl铆nico avanzado para m煤ltiples indicaciones.
Xenon Pharmaceuticals (NASDAQ : XENE), une entreprise biopharmaceutique sp茅cialis茅e en neurosciences, a annonc茅 sa participation 脿 la 46e conf茅rence annuelle mondiale sur la sant茅 de Goldman Sachs 脿 Miami, FL. Le PDG Ian Mortimer animera une discussion informelle le mardi 10 juin 2025, de 15h20 脿 15h55 (heure de l'Est). La pr茅sentation sera disponible en webcast sur le site web de Xenon. L'entreprise se concentre sur le d茅veloppement de produits ciblant les canaux ioniques pour l'茅pilepsie et la d茅pression, avec son principal candidat azetukalner, un activateur du canal potassique Kv7, en phase clinique avanc茅e pour plusieurs indications.
Xenon Pharmaceuticals (NASDAQ: XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, gab seine Teilnahme an der 46. j盲hrlichen globalen Gesundheitskonferenz von Goldman Sachs in Miami, FL, bekannt. CEO Ian Mortimer wird am Dienstag, den 10. Juni 2025, von 15:20 bis 15:55 Uhr ET ein Gespr盲ch im Kaminformat f眉hren. Die Pr盲sentation wird 眉ber einen Webcast auf der Website von Xenon verf眉gbar sein. Das Unternehmen konzentriert sich auf die Entwicklung von Ionenkanal-Produkten f眉r Epilepsie und Depression, wobei ihr f眉hrender Kandidat azetukalner, ein Kv7-Kaliumkanal枚ffner, sich in der sp盲ten klinischen Entwicklung f眉r mehrere Indikationen befindet.
Positive
None.
Negative
None.
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025.
Fireside Chat Presentation Details:
听
听
Date:
Tuesday, June 10, 2025
听
听
Time:
3:20-3:55 PM Eastern Time
听
听
Webcast:
听
听
Presenter:
Ian Mortimer, President and Chief Executive Officer
听
听
A live audio webcast of the company presentation will be available on the 鈥溾�� section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit .
鈥淴enon鈥� and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275
When is Xenon Pharmaceuticals (XENE) presenting at the Goldman Sachs Healthcare Conference 2025?
Xenon Pharmaceuticals will present on Tuesday, June 10, 2025, from 3:20-3:55 PM Eastern Time at the Goldman Sachs Healthcare Conference in Miami.
Who will be presenting for Xenon Pharmaceuticals (XENE) at the Goldman Sachs conference?
Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, will be presenting the fireside chat.
What is Xenon Pharmaceuticals' (XENE) main drug candidate?
Azetukalner, a novel Kv7 potassium channel opener, is Xenon's most advanced drug candidate in late-stage clinical development for multiple indications.
What therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?
Xenon Pharmaceuticals focuses on developing therapeutics for neuroscience conditions, particularly epilepsy and depression.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
